Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:57:53.089Z.
Calculation as of: 2026-10-06T17:57:53.089Z.
Quote observation: 2026-10-06T17:54:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$223.45M
EV/EBITDA Ratio
N/A
TTM Avg
1.40x
3Y Avg
1.40x
5Y Avg
1.40x
Market Cap
$216.82M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$232.01M
EV/EBITDA Ratio
N/A
TTM Avg
133.55x
3Y Avg
183129.66x
5Y Avg
183129.66x
Market Cap
$214.64M
EV/EBITDA Ratio
14.40x
TTM Avg
22.76x
3Y Avg
55.61x
5Y Avg
55.61x
Market Cap
$232.88M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $223.48M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $223.45M | N/A | 1.40x | 1.40x | 1.40x |
| Biodesix, Inc. (BDSX)vs › | $228.74M | N/A | N/A | N/A | N/A |
| Vogenx Inc. (VOGX)vs › | $229.03M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.01M | N/A | 133.55x | 183129.66x | 183129.66x |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 14.40x | 22.76x | 55.61x | 55.61x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.41M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.88M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $234.62M | N/A | 5.07x | 4.97x | 6.62x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
